Endo International PLC has reached an $8.75 million settlement with Oklahoma officials to resolve the generics and specialty pharmaceutical company's role in ongoing litigation over the U.S. opioid epidemic.

Malvern, Pa.-based Endo and its subsidiaries, Endo Pharmaceuticals Inc. and Par Pharmaceutical Inc., agreed with the state to settle all claims and resolve the investigation into the company's involvements in the opioid abuse crisis, according to a Jan. 10 press release. The company's senior leadership reached the agreement with Oklahoma Attorney General Mike Hunter and staff.

The settlement does not include an admission of any wrongdoing on the part of Endo.

A number of companies have reached settlements with states to resolve claims that certain marketing practices fueled the opioid epidemic, which kills about 200 Americans each day.